Bain- and Cinven-backed Stada buys 15 GSK brands

The purchase price is approximately €300m, according to Reuters. The deal is expected to close in Q2 2020.

Stada is looking to expand its presence in the over-the-counter (OTC) drugs market. GSK announced in February 2020 that it plans to spin off its consumer health joint venture with Pfizer. GSK plans to raise around £1bn by selling products off during the transition.

Bain and Cinven invested in Stada in August 2017, acquiring around 93.6% of its shares in a take-private valuing the company at €5.6bn. Cinven deployed equity from Cinven VI, which held a final close in June 2016 on €7bn.

Stada acquired five consumer brands from GSK in June 2019, including consumer skincare brands and pediatric cough liquids.

Stada reported sales from its consumer health and generic brands in 2018 totalling €2.33bn. In November 2019, Stada bought 20 OTC drug brands from Takeda for $660m.

Bain and Cinven declined to comment. A spokesperson for Stada declined to comment on the financing of the deal and the revenues of the portfolio.

Company
The consumer health brand portfolio is made up of 15 products in total. Venoruton, cold remedy Coldrex, vitamin C supplement Cetebe, the Mebucaine sore throat range and allergy treatment Tavegyl make up 50% of the total revenues from the group, according to a statement.

The brands are marketed in 40 countries, including Germany, Spain, Poland and Russia.

GSK is based in London and reported 2018 revenues from its pharmaceutical medicines, vaccines and consumer healthcare divisions of £30.82bn, comprising a total of £7.66bn from consumer healthcare.

People
Stada – Peter Goldschmidt (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Portfolio management
• DACH
• Healthcare
• Germany
• Bain Capital
• Cinven
• Build-up